Malhotra Sonali, Heptulla Rubina A, Homel Peter, Motaghedi Roja
1 Pediatric Endocrinology, Infant and Children's Hospital of Brooklyn, Maimonides Medical Center , Brooklyn, New York.
2 Pediatric Endocrinology, Children's Hospital at Montefiore , Bronx, New York.
Thyroid. 2017 Feb;27(2):167-173. doi: 10.1089/thy.2016.0197. Epub 2016 Dec 5.
Marijuana is legalized for medical use in 24 states and for recreational use in 5. However, effects of marijuana use on thyroid function and autoimmunity are unknown.
We performed a cross-sectional analysis of data from the National Health and Nutrition Examination Survey (NHANES) conducted between 2007 and 2012 to assess the effects of marijuana on thyroid function and autoimmunity in users. We included 5280 adults ages 18 to 69 years, who responded to questions related to marijuana use and had laboratory results related to thyroid parameters. Subjects were categorized as nonusers (never used), past users (used prior to 30 days ago), and recent users (used within last 30 days). Using NHANES normative cut offs for thyroid parameters, we compared recent users with nonusers and past users and calculated the odds ratios for the relative rate of clinically significant thyroid dysfunction in those groups. Multivariate logistic regression was then performed to control for confounders.
Fifty-four percent of subjects reported lifetime cannabis use, with 15% using it recently. Univariate regression analysis showed that recent marijuana users had significantly lower frequency of elevated thyrotropin (TSH) and positive anti-thyroperoxidase antibody (TPOAb) versus nonusers/past users. After controlling for confounders, recent marijuana use remained an independent predictor for TSH <5.6 μIU/mL (odds ratio of 0.344 with 95% CI of 0.127-0.928; p = 0.04) but not for negative TPOAb.
Recent marijuana use was not associated with thyroid dysfunction but was significantly associated with lower levels of TSH.
大麻在24个州被批准用于医疗用途,在5个州被批准用于娱乐用途。然而,大麻使用对甲状腺功能和自身免疫的影响尚不清楚。
我们对2007年至2012年期间进行的美国国家健康与营养检查调查(NHANES)的数据进行了横断面分析,以评估大麻对使用者甲状腺功能和自身免疫的影响。我们纳入了5280名年龄在18至69岁之间的成年人,他们回答了与大麻使用相关的问题,并拥有与甲状腺参数相关的实验室检查结果。受试者被分为非使用者(从未使用过)、既往使用者(在30天前使用过)和近期使用者(在过去30天内使用过)。使用NHANES甲状腺参数的正常临界值,我们将近期使用者与非使用者和既往使用者进行比较,并计算这些组中具有临床意义的甲状腺功能障碍相对发生率的比值比。然后进行多变量逻辑回归以控制混杂因素。
54%的受试者报告终生使用过大麻,其中15%为近期使用者。单变量回归分析显示,与非使用者/既往使用者相比,近期大麻使用者促甲状腺激素(TSH)升高和抗甲状腺过氧化物酶抗体(TPOAb)阳性的频率显著更低。在控制混杂因素后,近期使用大麻仍然是TSH<5.6μIU/mL的独立预测因素(比值比为0.344,95%置信区间为0.127-0.928;p=0.04),但不是TPOAb阴性的预测因素。
近期使用大麻与甲状腺功能障碍无关,但与较低的TSH水平显著相关。